BATS:HELX Franklin Genomic Advancements ETF (HELX) Price, Holdings, & News → Are you prepared for a Chinese 'invasion?' (From Behind the Markets) (Ad) Free HELX Stock Alerts $31.65 -0.03 (-0.09%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$31.41▼$31.6650-Day Range$29.32▼$32.3752-Week Range N/AVolume2,483 shsAverage VolumeN/AMarket Capitalization$9.49 millionAssets Under Management$9.51 millionDividend YieldN/ANet Expense Ratio0.50% Stock AnalysisStock AnalysisChartHoldingsRatingsStock AnalysisChartHoldingsRatings Get Franklin Genomic Advancements ETF alerts: Email Address About Franklin Genomic Advancements ETFThe Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that is based on the Solactive Genomics index. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is managed by Franklin Templeton.Read More HELX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HELX ETF News HeadlinesApril 23, 2024 | lse.co.ukFranklin Catholic Princ Em Sov Ucits Etf Share Price (CATHEM.MI)March 27, 2024 | money.usnews.comFranklin U.S. Treasury Bond ETFNovember 25, 2023 | lse.co.ukFranklin Msci China Paris Alig Ucits Etf Share Price (FRCP.MI)November 17, 2023 | lse.co.ukFranklin Emerging Markets Ucits Etf Share Price (FLXE.MI)February 25, 2023 | morningstar.comBMO ARK Genomic Revolution ETF SeriesSee More Headlines Receive HELX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Franklin Genomic Advancements ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerFranklin Templeton Investments Fund NameFranklin Genomic Advancements ETF Tax ClassificationRegulated Investment Company Stock ExchangeBATSCurrent SymbolBATS:HELX Inception Date2/25/2020 Fund ManagerMatthew J.Moberg, Joyce Lin WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings63 Fund Statistics Assets Under Management$9.51 million Average Daily Volume$0.00 Discount/Premium-0.02% Administrator, Advisor and Custodian AdministratorFranklin Templeton Services, LLC AdvisorFranklin Advisers, Inc. CustodianState Street Bank and Trust Company DistributorFranklin Templeton Distributors, Inc. Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerCitadel Miscellaneous Outstanding Shares300,000Beta1.00 Creation Unit50,000 Creation Fee$200.00 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Ad Behind the MarketsThis Weight Loss Company Can't Make Enough ProductA tiny pharmaceutical company is getting overwhelmed by a massive demand for its new weight loss marvel. They recently reported over 25,000 Americans are starting their drug each week - a 4X increase since December!Get the name of the company and their stock ticker here >>> Franklin Genomic Advancements ETF ExpensesTypeHELXTheme ETFsEquity ETFsBATS ETFsAll ETFsManagement Fee0.50%0.57%0.54%0.56%0.51%Other Expenses0.00%0.58%0.50%0.49%0.54%Total Expense0.50%0.73%0.70%0.70%0.71%Fee Waiver0.00%-0.76%-0.55%-0.37%-0.60%Net Expense0.50%0.60%0.60%0.64%0.58% Franklin Genomic Advancements ETF (HELX) Holdings & ExposureTop 10 HELX HoldingsMedpace(NASDAQ:MEDP)Holding Weight: 6.99%Vertex Pharmaceuticals(NASDAQ:VRTX)Holding Weight: 5.67%Danaher(NYSE:DHR)Holding Weight: 5.22%Regeneron Pharmaceuticals(NASDAQ:REGN)Holding Weight: 5.05%Thermo Fisher Scientific(NYSE:TMO)Holding Weight: 4.82%Eli Lilly and Company(NYSE:LLY)Holding Weight: 4.56%Krystal Biotech(NASDAQ:KRYS)Holding Weight: 4.01%Natera(NASDAQ:NTRA)Holding Weight: 3.41%Moderna(NASDAQ:MRNA)Holding Weight: 2.86%Samsung BioLogics Co LtdHolding Weight: 2.82%HELX Sector ExposureHELX Industry ExposureFull Holdings Details Similar ETFsOptica Rare Earths & Critical Materials ETFNYSEARCA:CRITB.A.D. EtfNYSEARCA:BADAmplify Treatments, Testing and Advancements ETFNYSEARCA:GERMHorizon Kinetics Blockchain Development ETFNYSEARCA:BCDFIQ Healthy Hearts ETFNYSEARCA:HART HELX ETF - Frequently Asked Questions How have HELX shares performed in 2024? Franklin Genomic Advancements ETF's stock was trading at $30.47 at the beginning of 2024. Since then, HELX shares have increased by 3.9% and is now trading at $31.6457. View the best growth stocks for 2024 here. What does HELX invest in? Franklin Genomic Advancements ETF is a equity fund issued by Franklin Templeton Investments. HELX focuses on theme investments. The fund's investments total to approximately $9.51 million assets under management. What stocks does Franklin Genomic Advancements ETF hold? HELX invests in 63 holdings. Some of the stocks in their portfolio include Medpace (MEDP), Vertex Pharmaceuticals (VRTX), Danaher (DHR), Regeneron Pharmaceuticals (REGN), Thermo Fisher Scientific (TMO), Eli Lilly and Company (LLY), Krystal Biotech (KRYS), Natera (NTRA), Moderna (MRNA) and AstraZeneca (AZN). What is the management fee for Franklin Genomic Advancements ETF? Franklin Genomic Advancements ETF's management fee is 0.50% and has no other recorded expenses or fee waivers. The net expense ratio for HELX is 0.50%. How do I buy shares of Franklin Genomic Advancements ETF? Shares of HELX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (BATS:HELX) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Franklin Genomic Advancements ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Franklin Genomic Advancements ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.